OKYO Pharma Chairman Boosts Stake, Advances Trials

OKYO Pharma Limited Sponsored ADR (OKYO) has released an update.

OKYO Pharma Limited announced the purchase of 80,000 ordinary shares by Panetta Partners Limited, an entity associated with its Executive Chairman Gabriele Cerrone, at $1.15 each, increasing his total ownership to 28.97%. The company, which is advancing innovative treatments for inflammatory dry eye disease and neuropathic corneal pain, has successfully completed a Phase 2 trial for its drug candidate OK-101 and is preparing for a Phase 2 trial to treat corneal neuropathic pain.

For further insights into OKYO stock, check out TipRanks’ Stock Analysis page.